- Home
- BYSI vs GANX Comparison
BYSI vs GANX Comparison
Compare BYSI & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- GANX
- Stock Information
- Founded
- BYSI 2010
- GANX 2017
- Country
- BYSI United States
- GANX United States
- Employees
- BYSI N/A
- GANX N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- BYSI Health Care
- GANX Health Care
- Exchange
- BYSI Nasdaq
- GANX Nasdaq
- Market Cap
- BYSI 73.4M
- GANX 79.8M
- IPO Year
- BYSI 2017
- GANX 2021
- Fundamental
- Price
- BYSI $1.79
- GANX $1.99
- Analyst Decision
- BYSI
- GANX Strong Buy
- Analyst Count
- BYSI 0
- GANX 6
- Target Price
- BYSI N/A
- GANX $8.00
- AVG Volume (30 Days)
- BYSI 35.0K
- GANX 835.3K
- Earning Date
- BYSI 11-11-2025
- GANX 11-13-2025
- Dividend Yield
- BYSI N/A
- GANX N/A
- EPS Growth
- BYSI N/A
- GANX N/A
- EPS
- BYSI N/A
- GANX N/A
- Revenue
- BYSI N/A
- GANX N/A
- Revenue This Year
- BYSI N/A
- GANX N/A
- Revenue Next Year
- BYSI N/A
- GANX N/A
- P/E Ratio
- BYSI N/A
- GANX N/A
- Revenue Growth
- BYSI N/A
- GANX N/A
- 52 Week Low
- BYSI $0.98
- GANX $1.41
- 52 Week High
- BYSI $3.44
- GANX $3.19
- Technical
- Relative Strength Index (RSI)
- BYSI 49.29
- GANX 58.08
- Support Level
- BYSI $1.72
- GANX $1.93
- Resistance Level
- BYSI $1.86
- GANX $2.40
- Average True Range (ATR)
- BYSI 0.07
- GANX 0.18
- MACD
- BYSI 0.01
- GANX 0.03
- Stochastic Oscillator
- BYSI 68.52
- GANX 46.53
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.